Two recombinant versions of CTX named CTX-KRKRK-GFP-H6 and CTX-GFP-H6, were developed by Díaz et al. [159] and investigated in two Human cancer cell lines previously identified as targets for CTX, namely HeLa (overexpressing Annexin A2) and U87 (overexpressing MMP2). Here, ANXA2 is linked to cancer.